Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD) (ALLSTAR)

15. september 2026 oppdatert av: GlaxoSmithKline

A Dose-finding, Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment With Efimosfermin Alfa in Adult Participants With Alcohol-related Liver Disease (ALD)

This is a dose-ranging study to evaluate safety of efimosfermin alfa and to establish proof-of-concept that efimosfermin alfa therapy provides benefit in participants with ALD.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

274

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

  • Forente stater
    • Kansas
      • Topeka, Kansas, Forente stater, 66606
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Shekhar Challa
        • Ta kontakt med:
        • Ta kontakt med:
    • Texas
      • Fort Worth, Texas, Forente stater, 76104
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas Cotter
      • San Antonio, Texas, Forente stater, 78215
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Eric Lawitz
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Participant must be 18 to 75 years of age inclusive, at the time of Screening.
  • Capable of giving signed informed consent prior to the performance of any study-specific procedures.
  • Able and willing to comply with all study assessments and adhere to the protocol schedule of activities.
  • History of heavy alcohol consumption for greater than 6 months at any time prior to Screening.

  • A female participant is eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:

    • Is a Participant of non-childbearing potential (PONCBP) OR
    • Is a Participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (<)1 percentage (%), 30 days prior to and during the study intervention period and for at least 16 weeks after the last dose of study intervention.

Exclusion Criteria:

  • Other primary causes of liver disease (e.g., viral hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, drug-induced hepatotoxicity, Wilson disease, hemochromatosis, alpha-1-antitryspin deficiency, etc.). Alcohol must be the primary cause of liver disease.
  • Co-infection with Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human immunodeficiency virus (HIV) as indicated from the central lab

  • History of diabetes mellitus (DM), either:

    • Type 1 DM
    • Type 2 DM with unstable glycemic control or with major complications.
  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the 3 years prior to Screening 1, regardless of any evidence of local recurrence or metastasis.
  • Current, or history of known hepatocellular carcinoma (HCC).
  • Any major surgery within 3 months prior to Screening 1 or planned during the study
  • Any surgical or medical condition that might jeopardize the individual's safety or compliance with study procedures in the opinion of the investigator.
  • All organ transplant recipients, except for history of corneal transplants, or current listing or active consideration for liver transplant during the Screening period.
  • Poorly controlled hypertension.
  • Evidence of Wernicke-Korsakoff syndrome or alcohol-related dementia.
  • Prior use of a Fibroblast growth factor 21 (FGF21) analogue, including efimosfermin, within the 6 months prior to Screening 1.
  • Individuals with a history of resmetirom use within 3 months prior to Day 1 are to be excluded.
  • Concomitant use of investigational drugs for Metabolic dysfunction-associated steatohepatitis (MASH) or ALD.
  • Current or planned participation in any clinical trial of investigational therapies or medical devices.
  • Exceeding pre-defined laboratory parameters for Triglycerides, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), International normalised ratio (INR), Albumin, Urine albumin-creatinine ratio (uACR) or Glycosylated Hemoglobin (HbA1c).
  • History of drug abuse within the 12 months prior to Day 1 or evidence of such abuse as indicated by laboratory assays conducted at Screening.
  • History of hypersensitivity (such as anaphylaxis or hepatotoxicity) to study intervention and/or its excipients, drugs of similar biological class, FGF21 protein analogs, Fc-fusion proteins, or other protein-based therapeutics.
  • Overt hepatic encephalopathy (West Haven grade >=2).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo
Deltakerne vil få placebo.
Legemiddel: Placebo
Placebo vil bli administrert.
Eksperimentell: Efimosfermin alfa Dose Level 1
Participants will receive efimosfermin alfa dose level 1.
Legemiddel: Efimosfermin alfa
Efimosfermin alfa will be administered.
Eksperimentell: Efimosfermin alfa Dose Level 2
Participants will receive efimosfermin alfa dose level 2.
Legemiddel: Efimosfermin alfa
Efimosfermin alfa will be administered.
Eksperimentell: Efimosfermin alfa Dose Level 3
Participants will receive efimosfermin alfa dose level 3.
Legemiddel: Efimosfermin alfa
Efimosfermin alfa will be administered.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in vibration-controlled transient elastography-liver stiffness measurement (VCTE-LSM)
Tidsramme: Baseline (Day 1) and up to Week 60
VCTE-LSM is a non-invasive test that uses vibration-controlled transient elastography to measure the stiffness of the liver in kilopascals (kPa)
Baseline (Day 1) and up to Week 60
Change from Baseline in model for end-stage liver disease (MELD) score
Tidsramme: Baseline (Day 1) and up to Week 60
MELD is a scoring system for assessing the severity of chronic liver disease. MELD scores range between 6 and 40, with 40 being the most severe.
Baseline (Day 1) and up to Week 60

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in serum aspartate aminotransferase (AST) (International units per liter)
Tidsramme: Baseline (Day 1) and up to Week 60
This is a measurement of the AST enzyme in the blood.
Baseline (Day 1) and up to Week 60
Change from Baseline in a blood test that helps predict the risk of disease progression in liver disease
Tidsramme: Baseline (Day 1) and up to Week 52
Baseline (Day 1) and up to Week 52
Trough Concentration at steady state (Ctrough,ss) following administration of efimosfermin alfa
Tidsramme: Up to Week 56
Up to Week 56
Area Under the concentration-time Curve from Time 0 (pre-dose) to the last quantifiable concentration (AUC[0-t]) of efimosfermin alfa in the subset of participants with optional intensive pharmacokinetics (PK) sampling
Tidsramme: Up to Week 4
Up to Week 4
Maximum observed drug concentration (Cmax) of efimosfermin alfa in the subset of participants with optional intensive PK sampling
Tidsramme: Up to Week 4
Up to Week 4
Number of Participants with Anti-drug antibodies (ADA) against efimosfermin alfa
Tidsramme: Up to Week 56
Up to Week 56
Number of participants with treatment-emergent adverse events (TEAEs) and TEAEs by severity
Tidsramme: Up to Week 60
Up to Week 60
Number of participants with TEAEs leading to discontinuation and TEAEs leading to discontinuation by severity
Tidsramme: Up to Week 60
Up to Week 60
Number of participants with Grade 3 and Grade 4 laboratory abnormalities
Tidsramme: Up to Week 60
Up to Week 60
Number of participants with clinically significant changes in Vital signs
Tidsramme: Up to Week 60
Up to Week 60
Number of participants with clinically significant changes in 12-lead electrocardiogram (ECG) findings
Tidsramme: Up to Week 60
Up to Week 60

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

GlaxoSmithKline

Etterforskere

  • Studieleder: GSK Clinical Trials, GlaxoSmithKline

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

31. august 2026

Primær fullføring (Antatt)

11. august 2028

Studiet fullført (Antatt)

14. januar 2030

Datoer for studieregistrering

Først innsendt

21. august 2026

Først innsendt som oppfylte QC-kriteriene

21. august 2026

Først lagt ut (Faktiske)

27. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 306837
  • 2026-526391-23 (Annen identifikator: EU CT Number)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD-delingstidsramme

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Tilgangskriterier for IPD-deling

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere